Physician profile
Brett E Stanaland
NPI 1508865924
$575,255.22
in general payments reported to CMS, 2019-2025
37 companies · $93K in 2025
The $93K reported for 2025 was more than what 97% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,443 · 2020: $41K · 2021: $61K · 2022: $53K · 2023: $128K · 2024: $196K · 2025: $93K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $358K · Travel and Lodging: $44K · Food and Beverage: $15K · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $358,241.25 |
| Travel and Lodging | $43,686.89 |
| Food and Beverage | $14,541.73 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $331,116.00 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $214,637.98 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Incyte Corporation | $11,288.00 | 2022-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $8,052.30 | 2019-2025 | Dupixent |
| Amgen INC. | $2,488.87 | 2022-2025 | Tezspire |
| Optinose US, INC. | $1,934.47 | 2019-2025 | |
| Genzyme Corporation | $1,022.40 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $681.35 | 2020-2025 | Hyqvia, Cuvitru, Eohilia |
| Genentech USA, INC. | $562.22 | 2019-2025 | Xolair |
| Csl Behring | $484.23 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Grifols USA, LLC | $438.57 | 2019-2024 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Pfizer INC. | $350.45 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $318.50 | 2019-2025 | |
| Covis Pharma Gmbh | $291.45 | 2019-2022 | |
| Kaleo, INC. | $195.84 | 2019-2023 | Auvi-Q |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Stanaland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.